If Vicore were a US-listed company, its valuation would be multiple times higher. The best proof is Pliant, a company in a similar state of development with much worse drug results. Vicore hired a new Boston-based CEO whose claim is to connect Vicore to a US investor base.
The new Vicore CEO is now starting to talk to US investors. He has a strong investment proposition – no other drug has ever had such strong results in IPF.
Vicore presentation at the Stifel conference – last week, Vicore CEO attended the Stifel 2023 Healthcare Conference in New York. The link to his PDF presentation is below:
The link to the presentation replay is below:
https://wsw.com/webcast/stifel83/vico/2098546
During the conference, the CEO will make a presentation to the whole conference, plus he will have an opportunity to have one-on-one meetings with certain investors.
What is positive – Vicore is getting invitations to such conferences. Stifel would not invite Vicore unless they believed they would be able to do trading with their stock or get a mandate for a future capital round.
We heard Vicore is attending a conference in February hosted by Guggenheim and are talking to other US-based brokers on investor roadshows.
This is all new for Vicore. Very new. Getting US investors on board is the first step to re-rate the Vicore share price.
Our family office believes Vicore is one of the holdings with the highest upside potential in our portfolio.
Do watch the webcast.
Disclosure:
The goal of the blog is to provide investment ideas for further research. I/we have a beneficial position in the shares discussed above either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. The article does not represent investment advice. Please do your own research before making any investment action.
Fit Investment Ideas 